B I09 is an IRE-1 RNase inhibitor (IC50: 1230 nM).

Treatment of CLL cells with this inhibitor (B I09) mimick XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. It also is highly effective in inhibiting splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS stimulated B cells [2].

B I09 has a halflife of approximately 1.5 hours and reaches its peak concentration of approximately 39 μM in mouse plasma serum 15 minutes after administration. Administration of B I09 to CLL tumor-bearing mice suppress leukemic progression by inducing apoptosis. It does not cause systemic toxicity [2].

1607803-67-7

C16H17NO5

303.31

B I09

DMSO:8.33 mg/mL (27.46 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years